BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 30261866)

  • 1. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
    Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F
    BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
    Conte B; Poggio F; Del Mastro L
    Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
    Goel S; Sharma R; Hamilton A; Beith J
    Cochrane Database Syst Rev; 2009 Oct; 2009(4):CD004562. PubMed ID: 19821328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
    Mathew A; Davidson NE
    Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
    Colleoni M; Munzone E
    Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant endocrine therapy in premenopausal patients with hormone receptor-positive early breast cancer: Evidence evaluation and GRADE recommendations by the Italian Association of Medical Oncology (AIOM).
    Gori S; Puglisi F; Cinquini M; Pappagallo G; Frassoldati A; Biganzoli L; Cortesi L; Fiorentino A; Angiolini C; Tinterri C; De Censi A; Levaggi A; Del Mastro L
    Eur J Cancer; 2018 Aug; 99():9-19. PubMed ID: 29886394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Standards, Options and Recommendations (SOR) for endocrine therapy in patients with non metastatic breast cancer. FNCLCC].
    Mauriac L; Blanc-Vincent MP; Luporsi E; Cutuli B; Fourquet A; Garbay JR; Giard S; Spyratos F; Zafrani B; Dilhuydy JM
    Bull Cancer; 2000 Jun; 87(6):469-90. PubMed ID: 10903789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
    Tan SH; Wolff AC
    Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Bao T; Davidson NE
    Breast Cancer Res; 2007; 9(6):115. PubMed ID: 18190722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
    Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
    Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete estrogen blockade for the treatment of metastatic and early stage breast cancer.
    Michaud LB; Buzdar AU
    Drugs Aging; 2000 Apr; 16(4):261-71. PubMed ID: 10874521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selecting adjuvant endocrine therapy for breast cancer.
    Eneman JD; Wood ME; Muss HB
    Oncology (Williston Park); 2004 Dec; 18(14):1733-44, discussion 1744-5, 1748, 1751-4. PubMed ID: 15700624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
    Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies in adjuvant endocrine treatment of premenopausal women.
    Goldstein LJ
    Clin Breast Cancer; 2006 Feb; 6 Suppl 2():S36-40. PubMed ID: 16595024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
    Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
    Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended therapy with letrozole and ovarian suppression in premenopausal patients with breast cancer after tamoxifen.
    Ruddy KJ; DeSantis SD; Barry W; Guo H; Block CC; Borges V; Winer EP; Partridge AH
    Clin Breast Cancer; 2014 Dec; 14(6):413-6. PubMed ID: 24970714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Which is the appropriate adjuvant endocrine therapy for premenopausal patients with breast cancer?
    Petrelli F; Barni S
    Clin Breast Cancer; 2015 Jun; 15(3):169-70. PubMed ID: 25600162
    [No Abstract]   [Full Text] [Related]  

  • 18. Adjuvant hormonal therapy and fertility preservation in premenopausal breast cancer: a survey among Italian oncologists.
    Barni S; CollovĂ  E; Frassoldati A; Amoroso D
    Future Oncol; 2015; 11(8):1181-9. PubMed ID: 25832875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal adjuvant endocrine therapy for early breast cancer.
    Stuart-Harris R; Davis A
    Womens Health (Lond); 2010 May; 6(3):383-98. PubMed ID: 20426605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
    Figg WD; Cook K; Clarke R
    Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.